Our team has come together to harness a new understanding of cellular biology in order to create a new way of treating disease.
Faze’s founders are global leaders in the field of biomolecular condensates who have conducted seminal work within this new scientific discipline. Faze’s leadership team brings together accomplished biotechnology executives with decades of industry experience and deep scientific, drug discovery and drug development knowledge.
Board of Directors
Entrepreneur in Residence, Third Rock Ventures
Adjunct Professor of Neurology and Psychiatry, Yale University School of Medicine
CSO, Kymera Therapeutics
Chief, Neurology Department, Massachusetts General Hospital
Senior Scientist & Program Head, Molecular Medicine, Hospital for Sick Children
Professor, Pharmaceutical Chemistry, Weill Institute for Neurosciences, UCSF
Associate Professor, St. Jude Children's Research Hospital
Partner, Third Rock Ventures
Assistant Professor, Molecular Genetics & Microbiology, University of Florida
New biological discoveries are exciting, but a key step to translate them into new medicines is the ability to identify a druggable target.
Faze’s technology for target identification is at the forefront of the field. Using a variety of screening and proteomics techniques, we are able to define condensate interaction networks. This map of condensate interactions reveals which protein play a central role in condensate regulation and suggests promising therapeutic targets.
Faze has built an unparalleled product engine to systematically understand and modulate condensates to treat disease:
DISCERN: Identify condensates at the root of a disease, and use a variety of screening and proteomics techniques to define key targets for regulation.
DISRUPT: Leverage proprietary assays to discover small molecules that can alter condensate pathologies, by targeting these key component proteins and regulators.
DEVELOP: Validate small molecules’ effects in proprietary assays and model systems, and advance them through clinical testing.
Our initial therapeutic focus areas are amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1), and we are also exploring other potential disease categories and indications that may benefit from our approach. A robust body of literature supports the characterization of both ALS and DM1 as diseases of condensate dysregulation.
Stay up to date with the latest news out of Faze.